ArticleJournal of cancer research and clinical oncology2025

Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.

Can Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.